Refresh Releases First of its Kind Eye Drop for Dry Eyes

Refresh Releases First of its Kind Eye Drop for Dry Eyes

Refresh Advanced OMEGA-3 Lubricant Eye Drops are the first eye drops on the market with omega-3 fatty acids

AbbVie (NYSE: ABBV), announced today the availability of Refresh Advanced OMEGA-3 Lubricant Eye Drops in Canada . The new, preservative-free eye drop is designed to provide rapid and long-lasting relief from dry eyes with the inclusion of natural omega-3 oil that helps lock in moisture.

Proven to relieve dryness, stinging and discomfort, the Refresh Advanced OMEGA-3 Lubricant Eye Drop is the first eye drop on the market with Omega-3 fatty acids. The natural omega-3 oil in this formulation is derived from flaxseed, a rich source of essential fatty acids. helping protect the eyes from further irritation.

"There are an estimated 6 million Canadians suffering from dry eye disease 1 ," says Dr. Courey. "The natural omega-3 oil in the new Refresh Advanced OMEGA-3 formulation helps lock-in moisture, offering a new option for those seeking lasting comfort."

In addition to dry eye disease, many Canadians face dry eyes due to exposure to wind or sun or a result of reduced blink frequency due to prolonged digital screen time.

Refresh Advanced OMEGA-3 Lubricant Eye Drops conveniently come in single-use 0.4 mL vials for easy on-the-go use. Refresh Advanced OMEGA-3 Lubricant Eye Drops can be found at major retailers across Canada .

For more information on the Refresh Advanced OMEGA-3 Eyedrops, please visit the product website at https://www.refreshbrand.ca/ .

About Refresh Advanced OMEGA-3 Eye drops

Refresh Advanced OMEGA-3 is indicated for the temporary relief of burning and irritation due to dryness of the eye and of discomfort due to minor irritation of the eye or to exposure to wind or sun. Refresh Advanced OMEGA-3 is also indicated for the relief of dry eyes and eye discomfort caused by reduced blink frequency due to prolonged digital screen time. This product may not be right for you. Always read and follow the label.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca . Follow AbbVie Canada on Twitter , on Instagram , or find us on LinkedIn .

CA-RFS-250038A

SOURCE AbbVie Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2025/11/c7577.html

News Provided by Canada Newswire via QuoteMedia

ABBV:US
The Conversation (0)
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Latest Press Releases

Related News